Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

1201 results about "Polyamine metabolism" patented technology

Polyamine Analogues. The critical role of polyamines in cell growth has led to the development of a number of agents that interfere with polyamine metabolism. These agents are used in cancer therapy. Polyamine analogues upregulate p53 in a cell leading to restriction of proliferation and apoptosis.

Detection of nucleic acids and nucleic acid units

PCT No. PCT/GB96/01830 Sec. 371 Date Apr. 21, 1998 Sec. 102(e) Date Apr. 21, 1998 PCT Filed Jul. 25, 1996 PCT Pub. No. WO97/05280 PCT Pub. Date Feb. 13, 1997The invention relates to the detection of target nucleic acids or nucleic acid units in a sample, by obtaining a SER(R)S spectrum for a SER(R)S-active complex containing, or derived directly from, the target. The complex includes at least a SER(R)S-active label, and optionally a target binding species containing a nucleic acid or nucleic acid unit. In this detection method, the concentration of the target present in the SER(R)S-active complex, or of the nucleic acid or unit contained in the target binding species in the SER(R)S-active complex, is no higher than 10-10 moles per liter. Additionally or alternatively, one or more of the following features may be used with the method: i) the introduction of a polyamine; ii) modification of the target, and/or of the nucleic acid or nucleic acid unit contained in the target binding species, in a manner that promotes or facilitates its chemi-sorption onto a SER(R)S-active surface; iii) inclusion of a chemi-sorptive functional group in the SER(R)S-active label. The invention also provides SER(R)S-active complexes for use in such a method, a kit for use in carrying out the method or preparing the complexes and a method for sequencing a nucleic acid which comprises the use of the detection method to detect at least one target nucleotide or sequence of nucleotides within the acid.
Owner:RENISHAW DIAGNOSTICS

Oligopeptide-free cell culture media

InactiveUS20070212770A1Efficient expression of recombinantEfficient productionFactor VIIBacteriaCulture cellCell culture media
The present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg / L of a polyamine and to methods for cultivating cells in said oligopeptide-free cell culture media comprising at least 0.5 mg / L of a polyamine. The invention also relates to methods for expressing at least one protein in a medium comprising at least 0.5 mg / L of a polyamine and to methods for producing at least one virus in a medium comprising at least 0.5 mg / L of a polyamine.
Owner:BAXTER HEALTHCARE SA +1

Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments

This invention defines a novel method for treatment of several neurological diseases and pathophysiologically related symptomology, said diseases including peripheral neuropathies, secondary symptomology of diabetes, Alzheimer's disease, Parkinson's disease, alcoholic polyneuropathy and age-onset symptomology, as well as analogous veterinary disease states. An opportunity exists for pharmacological intervention in some neurological diseases by use of water soluble, small molecular weight primary amine agents and chemical derivatives thereof. Examples of such primary pharmacological agents include 4-aminobenzoic acid and derivatives thereof. The present invention also includes: (1) oral use of optional non-absorbable polyamine polymeric co-agents such as chitosan, (2) oral use of optional known antioxidant co-agents and nutritional factors related thereto, and (3) use of the primary agents and co-agents noted above in optional combination with medicaments recognized as effective for treatment of the diseases addressed herein or symptoms thereof.
Owner:SECANT PHARMA

Methods of treating chronic inflammatory diseases using carbonyl trapping agents

InactiveUS6444221B1Improved therapeutic propertyImprove propertiesBiocidePeptide/protein ingredientsEtiologyBenzoic acid
These and other objects of this invention are achieved by providing a novel method and compositions for the clinical treatment of chronic inflammatory diseases. This invention involves use of systemically administered compositions which include primary amine derivatives of benzoic acid as carbonyl trapping agents. These primary therapeutic agents act by chemically binding to and sequestering the aldehyde and/or ketone products of lipid peroxidation. Increased levels of lipid peroxidation have been repeatedly demonstrated as a part of the non-enzymatic "inflammatory cascade" process which underlies the secondary etiology of chronic inflammatory diseases. p-Aminobenzoic acid (or PABA) is an example of the primary therapeutic agent of the present invention. PABA has a small molecular weight, is water soluble, has a primary amine group that reacts with carbonyl-containing metabolites under physiological conditions and is tolerated by the body in relatively high dosages and for extended periods. The carbonyl sequestering agents are used in combination with at least one co-agent so as to produce an additional beneficial physiological effect of an anti-inflammatory nature. Such compositions are administered systemically entirely via the oral route. Co-agents of the present invention include anti-oxidants and free radical trapping compounds (e.g., alpha-tocopherol), compounds having indirect anti-oxidant activity (e.g., selenium), vitamins (e.g., pyridoxine HCl), compounds which facilitate kidney drug elimination (e.g., glycine), metabolites at risk of depletion (e.g., pantothenic acid), sulfhydryl containing chemicals (e.g., methionine), compounds which facilitate glutathione activity (e.g., N-acetylcysteine), and non-absorbable polyamine co-agents (e.g., chitosan).
Owner:SECANT PHARMA

Cyanuric acid-based heavy metal chelating flocculant and preparation method thereof

InactiveCN101863544AOvercome the defect that the ion concentration is difficult to reach the standardIncrease steric hindranceWater/sewage treatment by flocculation/precipitationEpoxyHeavy metal chelation
The invention belongs to the technical field of heavy metal wastewater treatment, and in particular relates to cyanuric acid-based heavy metal chelating flocculant and a preparation method thereof. In the method, cyanuric acid is adopted as a basic framework; and polyamine is connected to a molecule through epoxy chloropropane, and reacts with carbon disulfide in an alkaline condition to prepare the heavy metal chelating flocculant of which the molecule contains a plurality of branches and a plurality of dithio formate functional groups. The method overcomes the defects that the conventional monofunctional flocculant has small flocculating body, and poor precipitation performance, and when polymeric chelant chelates heavy metals, steric clash is great, and the residual heavy metal ion concentration is difficult to meet the standard and the like. The flocculant has the advantages of simple preparation process, mild condition, easy operation and control, high yield, high raw material utilization, less three waste discharge and environmental protection of technical process, convenient popularization and industrialization realization and suitability for treatment of various types of heavy metal wastewater, such as smelting wastewater, electroplating wastewater, nonferrous metals processing wastewater, mining and beneficiating wastewater, printed circuit board wastewater, battery plants and the like.
Owner:HUNAN UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products